**Sanofi to Acquire BioNova's Partner Kadmon as BioNova Prepares for NDA for Rezurock in China**

On Sep 8, Sanofi S.A. (NYSE: SNY) announced to acquire Kadmon Holdings, Inc. (NASDAQ: KDMN) in $1.9 billion deal, adding Rezurock™(belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor for the treatment of chronic graft-versus-host disease (cGVHD) for adults and pediatric patients 12 years and older after failure of at least two prior lines of systemic therapy. In November 2019, BioNova Pharmaceuticals ('BioNova') and Kadmon entered into a strategic partnership to develop and commercialize Rezurock (belumosudil) for GVHD in China.

"Thanks to the growth of economy and healthcare standard, the number of patients who received stem cell transplant, as a potential curative therapy for certain hematologic malignancies, has been steadily increasing at a 20-30% annual rate over the past decade in China. Chronic GVHD presents a major post-transplant complication that can compromise long-term outcomes, and yet no approved therapy exists after first-line standard corticosteroid treatment in China." said Ye Hua, M.D., MPH, Founder, Chairman & CEO of BioNova, "The recent FDA Rezurock approval in the US and the latest Kadmon acquisition by Sanofi is a testimony to the clinical significance and commercial value of the drug. We are actively preparing for China NDA and hope to bring this important treatment to Chinese cGVHD patients in the near future."

"I had been following the Kadmon story for a long time and the science and novel mechanism of ROCK2 inhibition really caught my eyes. When we founded BioNova in October 2018, we already had a deep understanding of the drug and established a good relationship with Kadmon that really contributed to the successful partnership down the road." said Bryan Huang, Ph.D., MBA, Co-founder, CFO & CSO of BioNova, "It has been our consistent goal to focus on differentiated assets in disease areas with high unmet medical needs. While the program was still at very early stage, we made a decision to form the partnership after careful review of the limited clinical data and in-depth market research. The Rezurock story represents the first success of our strategy and hopefully we will have many more successful stories to come in the coming years."

Currently, BioNova is conducting a Phase 2 belumosudil (BN101) clinical trial for cGVHD in seven clinical centers in China and expecting to file NDA submission by the end of 2021.

**About cGVHD**

cGVHD is a common complication that can occur following allogeneic stem cell transplantation, causing transplanted immune cells (graft) attacking the patient's cells (host), resulting in inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. cGVHD can significantly lower patients' post-transplant quality of life, leading to patient death caused by a series of potential complications.

**About BioNova**

BioNova Pharmaceuticals (Shanghai) Limited is a privately-held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. Headquartered in Shanghai, BioNova is a fast-growing company with a robust pipeline built on internal R&D programs, collaborations with, and acquisitions from partners of cutting-edge technology. With a highly capable and seasoned team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.

For further information, please refer to https://www.bionovapharma.com

**Contact Us**
Claire Shan
IR & PR Manager
Email: claire.shan@bionovapharma.com
Tel: +86 (21) 5090 1280
Add: 2889 Jinke Road, Chamtime Plaza, Building B, Suite 905 Shanghai 201203, China